Remove Gene Expression Remove Packaging Remove Regulation Remove Research
article thumbnail

Moving the needle of CAR-T beyond oncology 

Drug Discovery World

Orchestrating the naturally occurring conductors of gene expression can shift the functional state of cells and alter gene expression. The epigenome is a system of reversible marks that regulate how the DNA is read, translated, and used. T-cells use epigenetic programs to regulate their maturation.

article thumbnail

FogPharma clears another big-ticket financing for its ‘miniprotein’ pipeline

pharmaphorum

Founded by prolific biotech entrepreneur and Harvard professor Gregory Verdine (pictured above) – along with WeiQing Zhou, John McGee, Professor Sir David Lane – FogPharma’s approach draws on research carried at Verdine’s Harvard lab on cell-penetrating miniproteins (CPMPs), of which Helicons are one class.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI-designed protein awakens silenced genes, one by one

The Pharma Data

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports.

Protein 52
article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields, providing a versatile tool for precise and efficient genome editing.

DNA 98
article thumbnail

Delivering on the promise of gene editing

Drug Discovery World

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Topping the list of alternatives are lipid nanoparticles (LNPs) and electroporation.